Abstract
Although factors involved in male sexual differentiation have been well studied, the pathways regulating female sexual differentiation remain incompletely defined. To date, no genes have been identified to play a similar role in ovarian development as was shown for the SRY or SOX9 genes in testicular development. In mice, Wnt4 regulates the development of the female reproductive tract, antagonizes the production of testosterone, and is important for oocyte development. The recent demonstration of heterozygous WNT4 defects in patients with Müllerian agenesis and signs of ovarian hyperandrogenism added WNT4 to the growing list of genes such as SRY, SOX9, WT1, DAX1, and SF-1 contributing to human sexual development. In particular, WNT4 was the first human gene to be identified to direct development of the bipotential gonad towards ovaries. From a more clinical point of view, it seems that the absence of a uterus (and not other Müllerian abnormalities) and the androgen excess are the pathognomonic signs of WNT4 defects, suggesting that WNT4 deficiency might be a clinical entity distinct from the typical Mayer-Rokitansky-Kuster-Hauser syndrome.
References
1.
Bertrand J, Rappaport R, Sizonenko PC: Pediatric Endocrinology, pp 88–99 (Williams & Wilkins, Baltimore 1993).
2.
Biason-Lauber A, Konrad D, Navratil F, Schoenle EJ: A WNT4 mutation associated with Mullerian-duct regression and virilization in a 46,XX woman. N Engl J Med 351:792–798 (2004).
3.
Biason-Lauber A, De Filippo G, Konrad D, Scarano G, Nazzaro A, Schoenle EJ: WNT4 deficiency – a clinical phenotype distinct from the classic Mayer-Rokitansky-Kuster-Hauser syndrome: a case report. Hum Reprod 22:224–229 (2007).
4.
Britt KL, Findlay JK: Regulation of the phenotype of ovarian somatic cells by estrogen. Mol Cell Endocrinol 202:11–17 (2003).
5.
Chand AL, Ponnampalam AP, Harris SE, Winship IM, Shelling AN: Mutational analysis of BMP15 and GDF9 as candidate genes for premature ovarian failure. Fertil Steril 86:1009–1012 (2006).
6.
Clement-Ziza M, Khen N, Gonzales J, Cretolle-Vastel C, Picard JY, et al: Exclusion of WNT4 as a major gene in Rokitansky-Kuster-Hauser anomaly. Am J Med Genet A 137:98–99 (2005).
7.
Couse JF, Hewitt SC, Bunch DO, Sar M, Walker VR, et al: Postnatal sex reversal of the ovaries in mice lacking estrogen receptors alpha and beta. Science 286:2328–2331 (1999).
8.
De La Chesnaye E, Kerr B, Paredes A, Merchant-Larios H, Mendez JP, Ojeda SR: Fbxw15/Fbxo12J is an F-box protein-encoding gene selectively expressed in oocytes of the mouse ovary. Biol Reprod 78:714–725 (2008).
9.
Di Pasquale E, Beck-Peccoz P, Persani L: Hypergonadotropic ovarian failure associated with an inherited mutation of human bone morphogenetic protein-15 (BMP15) gene. Am J Hum Genet 75:106–111 (2004).
10.
Di Pasquale E, Rossetti R, Marozzi A, Bodega B, Borgato S, et al: Identification of new variants of human BMP15 gene in a large cohort of women with premature ovarian failure. J Clin Endocrinol Metab 91:1976–1979 (2006).
11.
Dixit H, Rao LK, Padmalatha VV, Kanakavalli M, Deenadayal M, Gupta N, et al: Missense mutations in the BMP15 gene are associated with ovarian failure. Hum Genet 119:408–415 (2006).
12.
Domenice S, Corrêa RV, Costa EM, Nishi MY, Vilain E, et al: Mutations in the SRY, DAX1, SF1 and WNT4 genes in Brazilian sex-reversed patients. Braz J Med Biol Res 37:145–150 (2004).
13.
Dupont S, Krust A, Gansmuller A, Dierich A, Chambon P, Mark M: Effect of single and compound knockouts of estrogen receptors alpha (ERalpha) and beta (ERbeta) on mouse reproductive phenotypes. Development 127:4277–4291 (2000).
14.
Harris SE, Chand AL, Winship IM, Gersak K, Aittomaki K, Shelling AN: Identification of novel mutations in FOXL2 associated with premature ovarian failure. Mol Hum Reprod 8:729–733 (2002).
15.
He X, Semenov M, Tamai K, Zeng X: LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way. Development 131:1663–1677 (2004).
16.
Heikkila M, Peltoketo H, Leppaluoto J, Ilves M, Vuolteenaho O, Vainio S: Wnt-4 deficiency alters mouse adrenal cortex function, reducing aldosterone production. Endocrinology 143:4358–4365 (2002).
17.
Hughes IA: Female development – all by default? N Engl J Med 351:748–750 (2004).
18.
Jeays-Ward K, Hoyle C, Brennan J, Dandonneau M, Alldus G, et al: Endothelial and steroidogenic cell migration are regulated by WNT4 in the developing mammalian gonad. Development 130:3663–3670 (2003).
19.
Jordan BK, Mohammed M, Ching ST, Delot E, Chen XN, et al: Up-regulation of WNT-4 signaling and dosage-sensitive sex reversal in humans. Am J Hum Genet 68:1102–1109 (2001).
20.
Jordan BK, Shen JH, Olaso R, Ingraham HA, Vilain E: Wnt4 overexpression disrupts normal testicular vasculature and inhibits testosterone synthesis by repressing steroidogenic factor 1/beta-catenin synergy. Proc Natl Acad Sci USA 100:10866–10871 (2003).
21.
Jost A: Hormonal factors in the sex differentiation of the mammalian foetus. Phil Trans R Soc Lond B Biol Sci 259:119–130 (1970).
22.
Kovanci E, Rohozinski J, Simpson JL, Heard MJ, Bishop CE, Carson SA: Growth differentiating faxtor-9 mutations may be associated with premature ovarian failure. Fertil Steril 87:143–146 (2007).
23.
Liang L, Soyal SM, Dean J: FIGalpha, a germ cell specific transcription factor involved in the coordinate expression of the zona pellucida genes. Development 124:4939–4947 (1997).
24.
MacLaughlin DT, Donahoe PK: Sex determination and differentiation. N Engl J Med 350:367–378 (2004).
25.
Mandel H, Shemer R, Borochowitz ZU, Okopnik M, Knopf C, et al: SERKAL syndrome: an autosomal-recessive disorder caused by a loss-of-function mutation in WNT4. Am J Hum Genet 82:39–47 (2008).
26.
McElreavey K, Vilain E, Abbas N, Herskowitz I, Fellous M: A regulatory cascade hypothesis for mammalian sex determination: SRY represses a negative regulator of male development. Proc Natl Acad Sci USA 90:3368–3372 (1993).
27.
McLaren A: Meiosis and differentiation of mouse germ cells. Symp Soc Exp Biol 38:7–23 (1984).
28.
Merchant H: Rat gonadal and ovarian organogenesis with and without germ cells. An ultrastructural study. Dev Biol 44:1–21 (1975).
29.
Nusse R: Wnts and Hedgehogs: lipid-modified proteins and similarities in signaling mechanisms at the cell surface. Development 130:5297–5305 (2003).
30.
Palmer JS, Zhao ZZ, Hoekstra C, Hayward NK, Webb PM, et al: Novel variants in growth differentiation factor 9 in mothers of dizygotic twins. J Clin Endocrinol Metab 91:4713–4716 (2006).
31.
Pandur P, Lasche M, Eisenberg LM, Kuhl M: Wnt-11 activation of a non-canonical Wnt signalling pathway is required for cardiogenesis. Nature 418:636–641 (2002).
32.
Philibert P, Biason-Lauber A, Rouzier R, Pienkowski C, Paris F, et al: Identification and functional analysis of a new WNT4 gene mutation among 28 adolescent girls with primary amenorrhea and Mullerian duct abnormalities: a French collaborative study. J Clin Endocrinol Metab 93:895–900 (2008).
33.
Qin Y, Choi Y, Zhao H, Simpson JL, Chen ZJ, Rajkovic A: NOBOX homeobox mutation causes premature ovarian failure. Am J Hum Genet 81:576–581 (2007).
34.
Rajkovic A, Pangas SA, Ballow D, Suzumori N, Matzuk MM: NOBOX deficiency disrupts early folliculogenesis and oocyte-specific gene expression. Science 305:1157–1159 (2004).
35.
Soyal SM, Amleh A, Dean J: FIGalpha, a germ cell-specific transcription factor required for ovarian follicle formation. Development 127:4645–4654 (2000).
36.
Stenchever MA, Goldfarb AF: Atlas of Clinical Gynecology, Volume 1: Pediatric and Adolescent Gynecology (Appleton & Lange, U.S. 1998).
37.
Su YQ, Sugiura K, Wigglesworth K, O’Brien MJ, Affourtit JP, et al: Oocyte regulation of metabolic cooperativity between mouse cumulus cells and oocytes: BMP15 and GDF9 control cholesterol biosynthesis in cumulus cells. Development 135:111–121 (2008).
38.
Suwa T, Chen M, Hawks CL, Hornsby PJ: Zonal expression of dickkopf-3 and components of the Wnt signalling pathways in the human adrenal cortex. J Endocrinol 178:149–158 (2003).
39.
Vainio S, Heikkila M, Kispert A, Chin N, McMahon AP: Female development in mammals is regulated by Wnt-4 signalling. Nature 397:405–409 (1999).
40.
Wood JR, Ho CK, Nelson-Degrave VL, McAllister JM, Strauss JF 3rd: The molecular signature of polycystic ovary syndrome (PCOS) theca cells defined by gene expression profiling. J Reprod Immunol 63:51–60 (2004).
41.
Yao HH: The pathway to femaleness: current knowledge on embryonic development of the ovary. Mol Cell Endocrinol 230:87–93 (2005).
42.
Yao HH, Matzuk MM, Jorgez CJ, Menke DB, Page DC, et al: Follistatin operates downstream of Wnt4 in mammalian ovary organogenesis. Dev Dyn 230:210–215 (2004).
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
